Citations 166

P4‐298: IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID‐MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION‐OF‐INTEREST

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2014.07.069

P2‐141: BRAIN‐DERIVED NEUROTROPHIC FACTOR (BDNF) POLYMORPHISMS ARE ASSOCIATED WITH DIFFERENTIAL RATES OF AMYLOID ACCUMULATION AND COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_13 | Pages: No page available

10.1016/j.jalz.2014.05.816

Pituitary adenylate cyclase–activating polypeptide is reduced in Alzheimer disease

Neurology | April 10, 2014 | Volume: 82 | Issue: 19 | Pages: 1724-1728

10.1212/wnl.0000000000000417 | PMID 24719484

P4‐284: Independent and epistatic effects of Val66Met BDNF and ApoE polymorphisms on BETA‐AMYLOID deposition in cognitively normal individuals using PiB‐PET imaging

Alzheimer's & Dementia | March 29, 2014 | Volume: 8 | Issue: 4S_Part_21 | Pages: No page available

10.1016/j.jalz.2013.08.065

P1–334: Development and implementation of the National Alzheimer's Prevention Registry

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2013.05.560

DT‐01–06: Baseline FDG‐PET and volumetric MRI predicts Alzheimer's disease conversion from mild cognitive impairment: An ADNI study

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_21 | Pages: No page available

10.1016/j.jalz.2013.08.007

O2–03–01: Validation of the Alzheimer's Prevention Initiative Composite Cognitive Test Score

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2013.04.147

Fibrillar amyloid correlates of preclinical cognitive decline

Alzheimer's & Dementia | April 16, 2013 | Volume: 10 | Issue: 1 | Pages: No page available

10.1016/j.jalz.2013.01.009 | PMID 23583233

AbstractBackgroundIt is not known whether preclinical cognitive decline is associated with fibrillar β‐amyloid (Aβ) deposition irrespective of apolipoprotein E (APOE) ε4 status.MethodsFrom a prospective observational study of 623 cognitively normal individuals, we identified all subjects who showed preclinical decline of at least 2 standard deviations beyond the decline of the entire group in memory or executive function. Fourteen decliners were matched by APOE ε4 gene dose, age, sex, and education with 14 nondecliners. Dynamic Pittsburgh compound B (PiB) positron emission tomography (PET) scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest were used to characterize and compare cerebral‐to‐cerebellar PiB distribution volume ratios (DVRs), reflecting fibrillar Aβ burden.ResultsAt P < .005 (uncorrected), decliners had significantly greater DVRs in comparison to nondecliners.ConclusionsAsymptomatic longitudinal neuropsychological decline is associated with subsequent increased fibrillar amyloid deposition, even when controlling for APOE ε4 genotype.
Subjective cognitive decline: Self and informant comparisons

Alzheimer's & Dementia | April 4, 2013 | Volume: 10 | Issue: 1 | Pages: 93-98

10.1016/j.jalz.2013.01.003 | PMID 23562429

AbstractBackgroundIt is unclear whether self‐ or informant‐based subjective cognition better distinguishes emotional factors from early‐stage Alzheimer's disease (AD).MethodsHealthy members (n = 447) of the Arizona apolipoprotein E (APOE) cohort and their informants completed the self and informant paired Multidimensional Assessment of Neurodegenerative Symptoms questionnaire (MANS).ResultsDecline on the MANS was endorsed by 30.6% of members and 26.2% of informants. Self‐ and informant‐based decliners had higher scores of psychological distress and slightly lower cognitive scores than nondecliners. Over the next 6.7 years, 20 developed mild cognitive impairment (MCI). Converters were older at entry than nonconverters (63.8 [7.0] vs 58.8 [7.3] years, P = .003), 85% were APOE ε4 carriers (P < .0001), and they self‐endorsed decline earlier than informants (58.9 [39.2] vs 28.0 [40.4] months before MCI; P = .002).ConclusionsSelf‐ and informant‐based subjective decline correlated with greater psychological distress and slightly lower cognitive performance. Those with incident MCI generally self‐endorsed decline earlier than informants.
Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions

Neurology | March 28, 2013 | Volume: 80 | Issue: 17 | Pages: 1557-1564

10.1212/wnl.0b013e31828f17de | PMID 23535495